Future Tech
Mind-altering substances are (still) falling short in clinical trials
This week I want to look at where we are with psychedelics, the mind-altering substances that have somehow made the leap from counterculture to major focus of clinical research. Compounds like psilocybin—which is found in magic mushrooms—are being explored for all sorts of health...
MTR
MIT Technology Review
Source
MIT Technology ReviewRead the full story at MIT Technology Review

AI Analysis
Generated insight by OnAirToday AI
While psychedelics show promise for various mental health conditions, clinical trial outcomes reveal significant hurdles remain before widespread therapeutic adoption. Overcoming inconsistencies in efficacy and managing side effects are key challenges for translating this potential into reliable treatments.
Powered by AI • Not a substitute for human analysisMore Insights →
Share
Comments
Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.